Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Files Parkinson’s Drug Opicapone in Japan
February 28, 2019
- Eisai to Fund Japan NGO for Prevention of Infectious Diseases in Sudan
February 28, 2019
- Ono’s Braftovi/Mektovi Combo, Demser Now Available; Takeda’s Fibroid Drug to Hit Shelves on March 1
February 27, 2019
- BMS Seeks Japan Approval for New Empliciti Triplet
February 27, 2019
- Lonsurf Gets Gastric Cancer Nod in US
February 27, 2019
- AbbVie Files Japan NDA for Oral JAK Inhibitor
February 27, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Kowa’s Biz Realignment Reflects Globalization, Workstyle Reform, but No Job Cull Planned: President
February 27, 2019
- Roche Diagnostics Files PD-L1 Expression Assay for Use in Breast Cancer in Japan
February 27, 2019
- FunPep Gets Green Light for Clinical Study in Australia of Antibody-Inducing Peptide for Psoriasis
February 27, 2019
- Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
- Epclusa Hits Japan Market, 1st Drug for Hep C with Decompensated Cirrhosis
February 26, 2019
- Kentaro Murakawa Named as New President for Daiichi Sankyo Espha
February 26, 2019
- Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
- Shionogi Grabs European Nod for Naldemedine
February 25, 2019
- Daiichi Sankyo to Shake Up Organizations Focusing on Oncology R&D
February 25, 2019
- SanBio Vows to Continue Development of Stem Cell Therapy SB623 despite Setback: President
February 25, 2019
- Kyowa, Yoshitomi to Copromote Bipresso in Japan
February 22, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
- Japan Pharma Market Down 1.7% in 2018, with Maviret as Top-Selling Product: IQVIA Data
February 21, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…